Eli Lilly And Company  (LLY)
Other Ticker:  
Price: $374.7600 $4.43 1.196%
Day's High: $375.04 Week Perf: 2.46 %
Day's Low: $ 365.00 30 Day Perf: 5.58 %
Volume (M): 1,926 52 Wk High: $ 375.19
Volume (M$): $ 721,600 52 Wk Avg: $299.77
Open: $366.08 52 Wk Low: $231.87

 Market Capitalization (Millions $) 338,708
 Shares Outstanding (Millions) 904
 Employees 33,625
 Revenues (TTM) (Millions $) 29,240
 Net Income (TTM) (Millions $) 6,033
 Cash Flow (TTM) (Millions $) -1,171
 Capital Exp. (TTM) (Millions $) 1,645

Eli Lilly And Company
We discover, develop, manufacture, and sell products in one significant business segment—pharmaceutical products. Operations of our animal health business segment are not material to our financial statements. We manufacture and distribute our products through owned or leased facilities in the United States, Puerto Rico, and 17 other countries. Our products are sold in approximately 140 countries.

Most of the products we sell today were discovered or developed by our own scientists, and our success depends to a great extent on our ability to continue to discover and develop innovative new pharmaceutical products. We direct our research efforts primarily toward the search for products to prevent and treat human diseases. We also conduct research to find products to treat diseases in animals and to increase the efficiency of animal food production.

In the United States, we distribute pharmaceutical products principally through independent wholesale distributors. Our marketing policy is designed to assure that products and relevant medical information are immediately available to physicians, pharmacies, hospitals, and appropriate health care professionals throughout the country. Three wholesale distributors in the United States – AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. No other distributor accounted for more than 10 percent of consolidated net sales. We also sell pharmaceutical products directly to the United States government and other manufacturers, but those sales are not material.

We promote our major pharmaceutical products in the United States through sales representatives who call upon physicians, wholesalers, hospitals, managed-care organizations, retail pharmacists, and other health care professionals. We advertise in medical and drug journals, distribute literature and samples of certain products to physicians, and exhibit at medical meetings. In addition, we advertise certain products directly to consumers in the United States and we maintain web sites with information about all our major products. Divisions of our sales force are dedicated to product lines or practice areas, such as primary care, neuroscience, diabetes care, acute care, endocrinology, and oncology. We have entered into licensing arrangements under which other companies market certain products manufactured by us, such as Darvon, Sarafem, Axid, Keftab, Lorabid, and Permax.

Large purchasers of pharmaceuticals, such as managed-care groups and government and long-term care institutions, account for a significant portion of total pharmaceutical purchases in the United States. We have created special sales groups to service managed-care organizations, government and long-term care institutions, hospital contract administrators, and certain retail pharmacies. In response to competitive pressures, we have entered into arrangements with a number of these organizations providing for discounts or rebates on one or more Company products or other cost-sharing arrangements.

Outside the United States, we promote our pharmaceutical products primarily through sales representatives. While the products marketed vary from country to country, neuroscience products constitute the largest single group in total sales. Distribution patterns vary from country to country. In most countries, we maintain our own sales and distribution organizations. In some countries, however, we market our products through independent distributors.

Raw Materials and Product Supply

Most of the principal materials we use in our manufacturing operations are available from more than one source. We obtain certain raw materials principally from only one source. In addition, three of our significant products are manufactured by others: Actos by Takeda; ReoPro by Centocor; and Xigris by Lonza Biologics (bulk product) and DSM, N.V. (finished product). If we were unable to obtain certain materials from present sources, we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.


Our pharmaceutical products compete with products manufactured by many other companies in highly competitive markets throughout the world. Our animal health products compete on a worldwide basis with products of pharmaceutical, chemical, and other companies that operate animal health divisions or subsidiaries.

Important competitive factors include product efficacy, safety, and ease of use, price and demonstrated cost-effectiveness, marketing effectiveness, service, and research and development of new products and processes. If competitors introduce new products, delivery systems or processes with therapeutic or cost advantages, our products can be subject to progressive price reductions or decreased volume of sales, or both. Most new products that we introduce must compete with other products already on the market or products that are later developed by competitors. Manufacturers of generic pharmaceuticals typically invest far less in research and development than research-based pharmaceutical companies and therefore can price their products significantly lower than branded products. Accordingly, when a branded product loses its market exclusivity, it normally faces intense price competition from generic forms of the product. In many countries outside the United States, patent protection is weak or nonexistent and we must compete with generic or “knockoff” versions of our products.

   Company Address: Lilly Corporate Center Indianapolis 46285 IN
   Company Phone Number: 276-2000   Stock Exchange / Ticker: NYSE LLY
   LLY is expected to report next financial results on February 22, 2023.

Customers Net Income fell by LLY's Customers Net Profit Margin fell to

-15.03 %

3.55 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV        2.53% 
ABT        1.06% 
BMY        2.39% 
MRK        2.36% 
ACT        0.94% 
AMGN        0.62% 
• View Complete Report

Box Inc

Box Inc disclosed significant 11.563%, Sales rise , in the financial period ending October 31 2022

For the fiscal interval ending October 31 2022 BOX had turn a round to profitability by posting EPS of $0.03 per share compare to $-0.12 a year prior and earnings per share turned positive from $-0.02 per share from the previous quarter.

Sales were up by 11.563 % to $249.95 millions from $224.04 millions in the similar quarter a year prior and sequentially Sales increased by 1.6 % from $246.02 millions.

Kirkland S Inc

Extremely pressing quarter for the company in the third quarter of 2022

KIRK disclosed disastrous August to October 29 2022, where Sales faded by -77.242 % to $32.69 millions and net loss per share has extended to $-0.58, from the comparable quarter a year before.

Vmware Inc

Contraction in Earnings while Sales rose at the Vmware Inc amid the third quarter of 2022

Sales improvement of 2.326 %, could not prevent income decline of -44.33 % in the Oct 28 2022 report, compared to same quarter a year ago. Sales were at $3.21 billions and eps at $0.54.

Nutriband Inc

The company disclosed amazing earnings, amid the financial three months ending October 31 2022

Nutriband Inc announced very robust Sales elevation of 189.139 % year on year to $0.62 millions in the financial three months ending October 31 2022, but increased a deficit per share at $-0.14.

Cracker Barrel Old Country Store Inc

Earnings deteriorated while Sales inched up at the Cracker Barrel Old Country Store Inc in the fiscal three months ending October 28 2022

The Restaurants company reported conflicting earnings in the fiscal three months ending October 28 2022, where Sales inched up by 6.955 % to $839.52 millions relative to $784.93 millions on a year-over-year basis, while net profit per share plummeted by -45.39 % to $0.77 per share, off $1.41 in the prior year reporting period.


Eli Lilly's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Animal health
 Segment     of total Revenue
 Segment     of total Revenue
Other pharmaceutical
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Eli Lilly does not provide revenue guidance.

Earnings Outlook
Cracker Barrel Old Country Store Inc does not provide earnings estimates.

Geographic Revenue Dispersion
United States
Other foreign countries


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

CNFN's Profile

Stock Price

CNFN's Financials

Business Description


Charts & Quotes

CNFN's News


CNFN's Competitors

Customers & Markets

Economic Indicators

CNFN's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries




At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071